Literature DB >> 8042659

Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine.

J J Drabick1, R B Narayanan, J C Williams, J W Leduc, C A Nacy.   

Abstract

The relative role that humoral immunity plays in protection against infection with the intracellular bacterium, Francisella tularensis, remains controversial. Cellular immunity is thought to play the major and perhaps only role. The authors, in this article, investigate the immunologic and protective properties of immune serum collected from human recipients of the live tularemia vaccine (LVS). Sera of recipients of the vaccine demonstrated reactivity with the vaccine strain by enzyme-linked immunosorbent assay and Western blot analysis. This reactivity appeared to be directed primarily against the lipopolysaccharide of LVS and demonstrated complete cross-reactivity with fully virulent F. tularensis (Schu4). Pooled immune sera protected mice fully against a 10,000 LD50 challenge with the LVS strain relative to non-immune sera. The protection was abrogated by dilution or preadsorption with the LVS strain but not by preadsorption with Escherichia coli, which suggests specificity of protection. The authors conclude that antibodies to the LVS strain of F. tularensis are generated by live vaccination in humans and play a significant role in protection of mice against lethal challenge with the same organism. These antibodies crossreact completely with fully virulent F. tularensis, but whether they play a role in protection against fully virulent human tularemia strains requires further experimentation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8042659     DOI: 10.1097/00000441-199408000-00003

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  38 in total

1.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

2.  Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains.

Authors:  Gopi Mara-Koosham; Julie A Hutt; C Rick Lyons; Terry H Wu
Journal:  Infect Immun       Date:  2011-01-31       Impact factor: 3.441

3.  Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Authors:  Katharina Richard; Barbara J Mann; Aiping Qin; Eileen M Barry; Robert K Ernst; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2017-03-06

4.  Ex vivo antigen-pulsed PBMCs generate potent and long lasting immunity to infection when administered as a vaccine.

Authors:  Sudeep Kumar; Raju Sunagar; Giang Pham; Edmund J Gosselin; David Nalin
Journal:  Vaccine       Date:  2017-01-06       Impact factor: 3.641

5.  Structural analysis of a protective epitope of the Francisella tularensis O-polysaccharide.

Authors:  Michael J Rynkiewicz; Zhaohua Lu; Julia H Hui; Jacqueline Sharon; Barbara A Seaton
Journal:  Biochemistry       Date:  2012-07-02       Impact factor: 3.162

6.  Antibodies to both terminal and internal B-cell epitopes of Francisella tularensis O-polysaccharide produced by patients with tularemia.

Authors:  Zhaohua Lu; Hillary M Perkins; Jacqueline Sharon
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

7.  Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.

Authors:  Zhaohua Lu; Marly I Roche; Julia H Hui; Berkay Unal; Philip L Felgner; Sunita Gulati; Guillermo Madico; Jacqueline Sharon
Journal:  Immunol Lett       Date:  2007-08-08       Impact factor: 3.685

8.  Temporal transcriptional response during infection of type II alveolar epithelial cells with Francisella tularensis live vaccine strain (LVS) supports a general host suppression and bacterial uptake by macropinocytosis.

Authors:  Christopher E Bradburne; Anne B Verhoeven; Ganiraju C Manyam; Saira A Chaudhry; Eddie L Chang; Dzung C Thach; Charles L Bailey; Monique L van Hoek
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

Review 9.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

10.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.